Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Ramathibodi Hospital10 enrolled

Overview

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was \< 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cirrhosis, Liver AKI

Interventions

Dextran 40DRUG

Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Decompensated cirrhosis with acute kidney injury * Ager over 18 years old Exclusion Criteria: * Having chronic kidney disease, severe heart or lung disease, severe sepsis * Pregnant * Receiving nephrotoxic agents * Having history of allergic to Dextran

Outcomes

Primary Outcomes

AKI reversal

Reducing creatinine to below 1.5 mg/dl

Time frame: 2 weeks

Secondary Outcomes

Mortality

Death

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.